Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| V540B-002 | Other Identifier | MSD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later.
A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540B) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540B in healthy adults and if people tolerate it.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GARDASIL®9 (G9) | Active Comparator | Participants will receive vaccinations with G9. |
|
| V540B | Experimental | Participants will receive vaccinations with V540B. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GARDASIL®9 (G9) | Biological | Suspension administered via intramuscular (IM) injection |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to approximately 6 months |
| Number of Participants Who Experience a Solicited Systemic AE | Solicited systemic AEs include headache, fatigue, nausea, dizziness, muscle aches, joint pain. | Up to approximately 6 months |
| Immediate Reactions Occurring Within 30 Minutes After Any Vaccination | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to approximately 6 months |
| Number of Participants Who Experienced Unsolicited AEs | An unsolicited AE is an AE that was not solicited using a vaccine report card (VRC) and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs. | Up to approximately 7 months |
| Number of Participants Who Experienced a Serious Adverse Event | Serious adverse events (SAEs) include adverse events that result in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect. | Up to approximately 18 months |
| Number of Participants Who Experienced a Medically-Attended AE |
| Measure | Description | Time Frame |
|---|---|---|
| Total Immunoglobulin G (IgG) Geometric Mean Ratios (GMRs) for anti-HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 | Geometric mean ratio (GMR) of titers for participants vaccinated with V540B versus those who received G9 alone will be calculated. | Up to approximately 7 months |
Not provided
Inclusion Criteria:
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anaheim Clinical Trials ( Site 0002) | Anaheim | California | 92801 | United States | ||
| California Clinical Trials Medical Group managed by PAREXEL ( Site 0008) |
Not provided
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| V540B | Biological | Experimental vaccine and adjuvant administered via IM injection |
|
AEs in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. Routine visits are not considered medically-attended adverse events (MAAEs). Examples of routine visits include physical examination, wellness visits, or vaccinations. |
| Up to approximately 18 months |
| Number of Participants Who Experienced an Event of Clinical Interest | Events of clinical interest (ECIs) are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs). | Up to approximately 18 months |
| Glendale |
| California |
| 91206 |
| United States |
| Velocity Clinical Research, Hallandale Beach ( Site 0003) | Hallandale | Florida | 33009 | United States |
| Research Centers of America ( Hollywood ) ( Site 0001) | Hollywood | Florida | 33024 | United States |
| Velocity Clinical Research, Omaha ( Site 0005) | Omaha | Nebraska | 68134 | United States |